The FDA has advised doctors about new warnings of cardiac problems associated with Propulsid. They have told Janssen to revise the label to include new information about the cardiac risks associated with the drug and to recommend that other therapies for heartburn generally be used before prescribing Propulsid. Five times between the date the drug was approved and January 2000, the labeling for the drug was made progressively stronger, warning about life threatening reactions to use of the drug.
- About US
- Our Practice Areas